The aim was to determine whether the autoantibody profile in Black female lupus patients is associated with clinical subsets, fluctuates over time and/or reflects disease activity. A clinical comparison with Caucasian and Asian patients matched for age of onset and disease duration was also undertaken. Up to seven serial bleeds from Black female lupus patients who had been followed up for periods of 3-15 yr were tested for antibodies to Ro/SSA, La/SSB, Sm, RNP and ribosomal P using ELISA research assays. Significant differences in both clinical and serological profiles between the ethnic groups were found. Varying aspects of disease activity were linked to anti-DNA (renal, cardiovascular, global score), anti-ribosomal P (musculoskeletal, haematology) and anti-Sm (general) antibodies. There are differences in clinical and serological profiles amongst systemic lupus erythematosus patients of different ethnic origin. However, using the BILAG system, relatively few antibodies were found to reflect disease activity accurately in serial measurements.
S lupus erythematosus (SLE) is classified serologically by a diversity of autoantibodies, notably those recognizing targets within the nucleus [1] . Although recent observations have suggested that at least part of this diversity may be more apparent than real, nevertheless a number of distinct targets do exist, and several have been studied intensively. These targets include single-and double-stranded DNA, histones and phospholipids. The relative ease of developing enzyme-linked immunosorbent assays (ELISAs) has facilitated efforts to link the presence of these antibodies to disease activity in general, and to distinguish subsets of disease. Thus, it is widely agreed that patients with active renal disease invariably have raised levels of antibodies to double-stranded DNA (reviewed in [2] ) and those with a history of recurrent spontaneous miscarriages and thrombotic events have anti-phospholipid antibodies [3, 4] . Fluctuations in levels of antibodies to double-stranded DNA have also been shown to reflect global disease activity in some, though not all, patients [5, 6] .
The purification of other nuclear (and cytoplasmic) targets was somewhat delayed in comparison to the above autoantigens and, in consequence, the development of ELISAs for these targets has been slower. Thus, there are far fewer descriptions of fluctuations in the levels of autoantibodies to Ro/SSA, La/SSB, Sm, RNP and ribosomal P for example. Furthermore, it has been appreciated that most of the 60 or so disease activity indices developed over the past 40 yr have never been shown to be either valid or reliable [7] . This too has interfered with attempts to demonstrate links between autoantibody levels and both general disease activity and activity within an individual organ or system.
Another conundrum has been the apparent ethnic association of certain autoantibodies. Thus, antibodies to Sm are much commoner in lupus patients of Afro-Caribbean origin [8] and we have shown previously that a subset of Black female patients with nephritis is characterized by a distinct precipitin profile, consisting of anti-Ro, anti-Sm and anti-RNP, but not anti-La antibodies [9] .
In this study, we present a detailed analysis of 14 Afro-Caribbean patients (distinct from our previous study) who have been followed up clinically for periods of 3 to q15 yr, in the same department, using a very detailed activity index, the BILAG (British Isles Lupus Assessment Group) system, which has been shown to be both valid and reliable. It distinguishes individual organ or system involvement [10] and can be converted to provide a global activity score. Levels of autoantibodies to Ro/SSA, La/SSB, Sm, RNP and ribosomal P using sensitive ELISAs developed recently, and DNA and C3 levels (using standard laboratory techniques), have been measured on samples collected during the lengthy periods of follow-up in these patients. We have sought to determine whether the autoantibody profile in this group of patients is associated with particular clinical subsets, fluctuates over time and/or reflects disease activity. In addition, the cumulative historical features of two separate groups of Caucasian and Asian lupus patients, carefully matched for age of onset and duration of follow-up, are compared with the Afro-Caribbean patients.
METHODS
The Bloomsbury Lupus Clinic was established in 1978 for the long-term follow-up of patients with SLE. Details of the first 100 patients (mean follow-up period = 5 yr) have been reported elsewhere [8] . Over 200 patients have now been followed up. From this group, all of the Black patients (n = 14) with a minimum of 3 yr follow-up were selected for inclusion in this study. Throughout the follow-up period, detailed clinical information, separate from the hospital notes, has been obtained at each out-patient visit and a serum sample stored (at −20°C) on each occasion.
Involvement of the skin, musculoskeletal system, central nervous system (CNS), cardiovascular/ respiratory system, renal and haematological disease has been noted according to criteria published previously [11] . Other accompanying disorders, such as Sjo¨gren's syndrome and autoimmune thyroid disease, were also noted. Disease activity has been assessed using the BILAG system [10] which is based on the 'physician's intention to treat' principle. In brief, the system divides lupus activity into eight organs/ systems with a range of scores from 'A' (indicating the most active disease) to 'E' (no active disease in this system now or previously). The scoring system, whilst not intended to provide a global score, can be converted into one as follows: A = 9 points, B = 3, C = 1, D and E = 0. Thus, a maximum of 72 points can be scored. The results of the BILAG global score method have been shown to compare well with other global score systems such as SLAM and SLEDAI [12] .
In order to contrast the range of clinical and serological features seen in Black patients, we have chosen an equal number of Caucasian and Asian patients from the clinic, selecting the best possible matches for age at onset and period of follow-up (Table I) . For the purposes of this study, the routine laboratory serology results were analysed (Table I) . From 1978 to 1988, a radioimmunoassay (Amersham, UK) was used in the serial measurement of anti-DNA antibody levels. From April 1988, we have used an ELISA (Cambridge Life Sciences). In each case, we regarded twice the upper limit of normal (25 and 100 U, respectively) recommended by the manufacturers as a high level. Three high levels were required before a patient was recorded as DNA antibody positive. Patients had approximately annual re-assessments of antibodies to Ro/SSA, La/SSB, Sm and RNP [originally by counter-immunoelectrophoresis, but for the past 7 yr by ELISA (Shield Diagnostics, Dundee)] as well as repeated Coombs' tests, rheumatoid factor assessments and lupus anti-coagulants. The assays used have been described in detail elsewhere [18, 13, 14] .
For the long-term follow-up serological part of this study, we have used the routine DNA antibody and serum C3 results (measured by laser nephelometer using UK approved standards, normal range 0.75-1.75 mg/ml; three reduced levels were required before the patient was regarded as being 'low' C3). The C3 levels were expressed as a proportion of the lower limit of normal and (because of the change in assay) the DNA binding antibodies as a fraction of the upper limit of normal (i.e. irrespective of the assay). For the research ELISAs (described below) to Ro, La, Sm, RNP and ribosomal P, between four and seven bleeds from each of the 14 Black patients with SLE were selected at random during the follow-up period (ranging from 3 to 15 yr, mean = 7.2, .. = 3.7). Disease activity in each organ/system was recorded using the BILAG system and a global score determined as above. Solid-phase assays for anti-Ro/SSA [24] , anti-La/ SSB [25] and anti-U 1 RNP and anti-Sm [26] were performed using affinity-purified antigens prepared from calf thymus tissue extract. Solid-phase assays for anti-ribosomal 'P' and Western blotting were performed as previously described [27] .
Statistics
Simple Pearson correlation coefficients were used to identify relationships of potential interest, but all correlations were repeated using the Spearman rank correlation test. Chi square analysis with Yates' correction for small numbers was used as appropriate. Table I confirms that the 14 patients in each of the Caucasian, Black and Asian groups were matched closely with respect to age at diagnosis and period of follow-up. Clinically, some differences between the groups are readily apparent. Thus, the Caucasian patients were the most likely to have skin disease and severe thrombocytopenia, but the least likely to have involvement of the CNS and kidneys. The Black patients were the most likely to have CNS, renal disease and Sjo¨gren's syndrome. There was little difference between the groups with respect to the frequency of musculoskeletal or cardiovascular/respiratory disease, or complicating autoimmune thyroid disease. In terms of outcome in the Black, Asian and Caucasian groups, there were two, one and two deaths, respectively. Two Black patients and one Asian patient have developed renal failure, but none of the Caucasians to date.
RESULTS
Serologically, the three groups were homogeneous with respect to the frequency of antibodies to DNA, La/SSB, cardiolipin, and thyroid antigens and a positive Coombs' test. In contrast, the Black patients were much more likely to have antibodies to Sm and RNP (especially compared to the Caucasian patients), but less likely to be rheumatoid factor and lupus anti-coagulant positive. The Asian patients had the lowest prevalence of anti-Ro/SSA antibodies.
Assessment of the serial bleeds from the Black patients using the more sensitive research ELISAs leads to several general observations. Firstly, for a group of patients with SLE, the individuals were remarkably homogeneous serologically. Of the 14 patients, 13 had elevated levels of both anti-Ro/SSA and nRNP, and these were all inhibitable q50% by affinity-purified antigen in the fluid phase. Secondly, although anti-La/SSB antibodies were marginally elevated Numbers here are the ratio of the highest titre to the lowest titre sample for a given patient. Patient 13 had elevation of either anti-Ro/SSA nor anti-nRNP.
statistically in 10 out of 14 patients, in none could significant inhibition be demonstrated in the fluid phase (and only one patient was anti-La/SSB positive by the commercial ELISA). Anti-Sm was present in high titre in one patient and in low titre in four others. However, even in the low-titre positive patients, there was evidence of q50% inhibition by affinity-purified antigen in the fluid phase inhibition assays. Each of the five patients with anti-Sm antibodies also had anti-Ro/SSA and anti-RNP antibodies (without accompanying anti-La/SSB antibodies). Three of these patients had renal disease and two did not. In contrast, four patients with renal disease lacked the three antibodies together (though each of them had anti-Ro/SSA and anti-RNP antibodies). Five Black patients had neither evidence of renal disease nor anti-Sm antibodies.
Anti-ribosomal P antibodies were present in low but elevated titre in three patients (only one of whom had CNS disease). All three had elevated levels by ELISA (and were more than 50% inhibited by soluble peptide) and bound a 38 kDa (Po) band in Western blots of rabbit ribosomes. Interestingly, two of these patients also had anti-Sm. Levels of antibodies to Ro/SSA and RNP fluctuated quite markedly, and often in tandem, in some but not all patients (see Table II ).
The comparison in the Black patients between the laboratory results and the BILAG scores (for each organ/system separately and as a global score) revealed (Table III) . Anti-DNA antibody levels correlated strongly with renal and cardiovascular respiratory disease and to a lesser extent with BILAG global score. Anti-ribosomal P antibody levels correl-ated with haematological disease and, very weakly, with musculoskeletal disease (although the statistical significance of this correlation was lost when applying the Bonferroni correction; data not shown). There was no correlation between anti-ribosomal P and CNS disease. Anti-Sm antibody levels did correlate with the 'General' BILAG disease category and showed a negative correlation with the C3 levels (r = − 0.59, P = 0.008). C3 levels also correlated with DNA antibody levels (r = − 0.34, P = 0.007). Anti-DNA antibody levels correlated with anti-ribosomal P values (r = 0.61, P = 0.02) and these latter antibodies correlated with anti-RNP antibodies (r = 0.60, P = 0.005). In contrast, there were no positive correlations between any other autoantibodies and clinical features or between the antibodies themselves. DISCUSSION In the past 40 yr, there have been innumerable attempts to link the presence of particular antibodies detectable in the serum of patients with lupus to clinical features of the disease. These attempts have been constrained by inadequacies of both laboratory assay techniques and the methods used to assess disease activity. With the introduction of reproducible, sensitive ELISAs, and the use of validated and reliable disease activity index, the present study has attempted to overcome these obstacles.
Having demonstrated previously [12] that a group of Black lupus patients with nephritis was more likely than a Caucasian group of patients to have a serological profile of anti-Ro/SSA, anti-Sm and anti-RNP, we sought to extend these observations. By examining sera collected over a long follow-up period from an additional group of Black patients, we wished to confirm our original observations and to determine whether fluctuations in these antibody levels, reminiscent of anti-DNA antibodies, were occurring and if they reflected changes in disease activity.
The results in this study confirm our earlier observations that lupus nephritis is found rarely in patients with both anti-Ro/SSA and anti-La antibodies [15, 16] . However, the association between the presence of anti-Sm, anti-Ro/SSA and anti-RNP with renal disease was not as clear cut as in the original study [9] . Another group [17] also failed to find such an association. The reasons for the disparity are likely to be multiple. As noted elsewhere [18] , it is optimal to test the serum in patients with untreated disease at presentation (which we were not able to do in this study) since the autoantibody profile may change. Furthermore, Black patients are not genetically homogeneous and this too may be important given that genes help to determine the autoantibodies that are expressed [19] . Finally, different assays may give different results. Thus, although there was very good correlation between the commercial and research ELISAs for the absence of anti-La/SSB antibodies, in the research ELISA 13 patients were anti-Ro/SSA and anti-RNP positive, whereas only 10 and 8 patients, respectively, were positive in the commercial assay.
Even with the more sensitive ELISAs used in this study, relatively few correlations were found with disease activity either in general or in individual organs/systems. As might have been anticipated, anti-DNA antibodies correlated the most strongly with renal disease, and to a lesser extent with cardiovascular manifestations and global score. However, Ro/SSA, La/SSB and RNP antibodies showed no correlations with clinical features, although anti-Sm antibody levels did correlate with 'General' lupus activity (principally fever, lymphadenopathy, weight loss). Serial measurement of these antibodies would thus appear to offer little help to the clinician in assessing lupus activity. Anti-ribosomal P antibodies showed a minor association with musculoskeletal disease, though none with CNS disease, also suggesting that repeated estimation of their levels is unlikely to be of much practical use. Their presence was, however, correlated with anti-RNP and anti-DNA antibodies.
Comparison of the prevalence rate of clinical features or serological abnormalities between groups of lupus patients rarely takes account of the age of onset of the patients or the duration of their disease. Both factors are important, however. Lupus occurring in older populations, for example, is much less likely to involve the CNS, but much more likely to be complicated by Sjo¨gren's syndrome for example [20, 21] .
With increasing duration of follow-up, new features of lupus have been shown to emerge at rates that vary with both age and ethnic group [22] . In the present study, we took the opportunity to review the clinical features and serological profiles of patients with lupus from three ethnic groups who had been very carefully matched for age of onset and duration of follow-up. While the number of patients (n = 14) is relatively small, we are unaware of any previous attempt to explore such differences in patients matched as well in this way.
In larger unmatched studies, Black patients were shown to be more likely to develop renal and CNS manifestations. Our results confirm these observations and emphasize the potential increased risk to these patients of developing antibodies to Sm and RNP. In contrast, the Caucasian patients (amongst whom anti-Sm antibodies are found occasionally) were the least likely to develop CNS disease, but the most likely to develop dermatological involvement, severe thrombocytopenia and antithyroid antibodies (though not autoimmune thyroid disease). The Asian patients were the least likely to suffer skin disease, thrombocytopenia or cardiovascular/respiratory problems, but the most likely to have sustained low C3 levels. In the main, the prevalence of lupus clinical features and serological abnormalities in this group was intermediate between that of the Black and Caucasian groups.
